Tyra Biosciences Receives IND Clearance from FDA to Proceed …
8 hours ago · TYRA-300 is a potential first-in-class, investigational, oral, FGFR3-selective inhibitor designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic ...
Tyra Biosciences Receives IND Clearance from FDA to Proceed …
8 hours ago · News provided by Tyra Biosciences Jan 10, 2025, 08:00 ET. Share this article. Share to X. Share this article. Share to X -TYRA appoints ...
Tyra Biosciences (TYRA) Receives IND Clearance from FDA to …
7 hours ago · FREE Breaking News Alerts from StreetInsider.com! E-mail Address. StreetInsider.com Top Tickers, 1/10/2025 ... with 60-80% of IR NMIBC showing alterations. TYRA-300 is expected to be evaluated in ...
Tyra Biosciences Receives IND Clearance from FDA to Proceed …
8 hours ago · CARLSBAD, Calif., Jan. 10, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for ...
FDA greenlights phase 2 SURF302 trial of TYRA-300 in NMIBC
21 hours ago · "Receiving FDA IND clearance is an important milestone in the advancement of TYRA-300 and for patients with NMIBC who urgently need better tolerated therapeutic options," said Doug Warner, chief medical officer of TYRA, in the news release. 1 "We look forward to leveraging Erik's impressive background to guide our development plans in NMIBC. We ...
Tyra Biosciences, Inc. - MarketScreener.com
7 hours ago · News Tyra Biosciences, Inc. Tyra Biosciences, Inc. Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer. Best financial portal +951% of historical performance More than 20 years at your side ...
Tyra Biosciences advances bladder cancer drug trial
7 hours ago · In other recent news, Tyra Biosciences has made significant strides in its clinical trials and financial prospects. The company's drug candidate, TYRA-300, has received FDA approval to proceed ...
Tyra Biosciences, Inc. (TYRA) Latest Stock News & Headlines
Get the latest Tyra Biosciences, Inc. (TYRA) stock news and headlines to help you in your trading and investing decisions.
Tyra Looks to Challenge J&J’s Balversa With Early Data for FGFR3 ...
Oct 25, 2024 · Tyra Biosciences on Thursday unveiled early proof-of-concept data for its investigational and potential first-in-class FGFR3 inhibitor TYRA-300, touting “encouraging” anti-tumor action in heavily pretreated patients with metastatic urothelial carcinoma.
Tyra Biosciences Announces Late-Breaking Oral Presentation on ...
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth...
- Some results have been removed